Inloggen

Login
 
Wachtwoord vergeten?

Kiadis Pharma mei 2019

Volgen
 
Klik hier om dit forumtopic te volgen en automatisch op de hoogte gehouden te worden bij nieuwe berichten.
1.360 Posts, Pagina: « 1 2 3 4 5 6 ... 45 46 47 48 49 50 51 52 53 54 55 ... 64 65 66 67 68 » | Laatste
Aantal posts per pagina:  20 50 100 | Omlaag ↓
BassieNL
0
Verwatering of niet. De goedkeuring BAVA kwam niet onverwacht. Dat zat dus al lang in de koers verwerkt. No big deal.
Rotel74
0
(ABM FN-Dow Jones) FIL Limited heeft een kleiner belang in Kiadis Pharma gemeld. Dit bleek uit een melding in het kader van de Nederlandse Wet op het financieel toezicht, gedateerd op 28 mei 2019.

FIL meldde een kapitaalbelang van 2,96 procent met een zelfde stemrecht. Het belang wordt middellijk reëel gehouden.

Op 19 oktober vorig jaar meldde FIL nog een kapitaalbelang van 4,40 procent met een stemrecht van 2,83 procent.

Wet op het financieel toezicht

De melding valt onder de Wet melding zeggenschap, die sinds 1 januari 2007 onder de overkoepelende Wet op het financieel toezicht valt. Volgens deze wet moeten aandeelhouders met een belang groter dan 3 procent elke wijziging in hun belang melden bij het overschrijden van de volgende drempelwaarden: 3, 5, 10, 15, 20, 25, 30, 40, 50, 60, 75 en 95 procent. Dit geldt zowel bij het opbouwen als het afbouwen van een belang.

Door: ABM Financial News.
info@abmfn.nl
Redactie: +31(0)20 26 28 999

De newsfeed is tenminste 15 minuten vertraagd en is een beperkte weergave van de totale webfeed die ABM Financial News levert.

© Copyright ABM Financial News B.V. All rights reserved. Any redistribution, duplication or archiving prohibited. ABM Financial News B.V. and the provider of this website/application do not warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or delays in the content, or for any actions taken in reliance thereon.

Endless
0
quote:

Rotel74 schreef op 30 mei 2019 om 08:40:


(ABM FN-Dow Jones) FIL Limited heeft een kleiner belang in Kiadis Pharma gemeld. Dit bleek uit een melding in het kader van de Nederlandse Wet op het financieel toezicht, gedateerd op 28 mei 2019.

FIL meldde een kapitaalbelang van 2,96 procent met een zelfde stemrecht. Het belang wordt middellijk reëel gehouden.

Op 19 oktober vorig jaar meldde FIL nog een kapitaalbelang van 4,40 procent met een stemrecht van 2,83 procent.

Wet op het financieel toezicht

De melding valt onder de Wet melding zeggenschap, die sinds 1 januari 2007 onder de overkoepelende Wet op het financieel toezicht valt. Volgens deze wet moeten aandeelhouders met een belang groter dan 3 procent elke wijziging in hun belang melden bij het overschrijden van de volgende drempelwaarden: 3, 5, 10, 15, 20, 25, 30, 40, 50, 60, 75 en 95 procent. Dit geldt zowel bij het opbouwen als het afbouwen van een belang.

Door: ABM Financial News.
info@abmfn.nl
Redactie: +31(0)20 26 28 999

De newsfeed is tenminste 15 minuten vertraagd en is een beperkte weergave van de totale webfeed die ABM Financial News levert.

© Copyright ABM Financial News B.V. All rights reserved. Any redistribution, duplication or archiving prohibited. ABM Financial News B.V. and the provider of this website/application do not warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or delays in the content, or for any actions taken in reliance thereon.



Is hun belang niet automatisch kleiner geworden door die 1,95 miljoen nieuwe aandelen?
galaking
0
Hun belang is niet automatisch kleiner geworden, want de aandelen aan Cytosen worden pas overgedragen als de deal helemaal afgerond is en dat is naar verwachting van Kiadis eind juni.
Endless
0
quote:

galaking schreef op 30 mei 2019 om 09:10:


Hun belang is niet automatisch kleiner geworden, want de aandelen aan Cytosen worden pas overgedragen als de deal helemaal afgerond is en dat is naar verwachting van Kiadis eind juni.

Is dat zo? Want als de warrant gisteren al effectief zijn geworden is er al de verwatering ongeacht bij welke eigenaar ze liggen, lijkt me ? Ik hoop op een mooie groene dag want we gaan op naar het positief CHMP advies
Huil maar niet
0
quote:

Endless schreef op 30 mei 2019 om 09:00:


[...]
Is hun belang niet automatisch kleiner geworden door die 1,95 miljoen nieuwe aandelen?
Helder op gemerkt.
Elvisfan
0
quote:

BassieNL schreef op 30 mei 2019 om 11:43:


Vergelijk de laatste 2 AFM meldingen. Ze hebben wel degelijk aandelen verkocht.
www.afm.nl/nl-nl/professionals/regist...
www.afm.nl/nl-nl/professionals/regist...



hmmm, vreemd, net voor een 'eventuele' goedkeuring ....
Zjadni
0
BassieNL
0
Bij hun vorige melding hadden ze minder stemrecht dan aandelen.
Wat zou dat betekenen?
createmonnie
0
quote:

BassieNL schreef op 30 mei 2019 om 11:58:


Bij hun vorige melding hadden ze minder stemrecht dan aandelen.
Wat zou dat betekenen?



Je zal zelf het antwoord wel weten Bassie, maar meer gewone aandelen verkocht en premium aandelen gekocht
Kogovus
0
quote:

createmonnie schreef op 30 mei 2019 om 14:15:


[...]

Je zal zelf het antwoord wel weten Bassie, maar meer gewone aandelen verkocht en premium aandelen gekocht


Nu zonder cryptische omschrijving??? Wat houdt het volgens jullie in?
Elvisfan
0
quote:

PGV schreef op 30 mei 2019 om 15:39:


Had wel wat herstel verwacht vandaag.


waarom?
createmonnie
0
quote:

Kogovus schreef op 30 mei 2019 om 15:46:


[...]

Nu zonder cryptische omschrijving??? Wat houdt het volgens jullie in?


risico verlagen, zonder stemrecht te verliezen. Het zullen spannende dagen/weken worden.
Endless
0
quote:

PGV schreef op 30 mei 2019 om 15:39:


Had wel wat herstel verwacht vandaag.

Nu die nieuwe deeltjes de markt aan het komen zijn ,blijft er tot die tijd de koersdruk bestaan . Positief advies gaan we weer substantieel omhoog want dan zijn deze deeltjes op de markt. Nu even door de zure appel maar zelf sta ik achter de deal, want LT gaat dit in mijn optiek een grote aanwinst voor Kiadis betekenen.
Bio-belegger
1
Kiadis Pharma : launches a private placement of new shares to raise approximately EUR 25 million
Envoyer par e-mail
05/30/2019 | 05:45 pm
Not for release, publication or distribution, directly or indirectly, in or into the United States, Australia, Canada, Japan, south africa or Any other jurisdiction in which such release, publication or distribution would be unlawful



Kiadis Pharma launches a private placement of new shares to raise
approximately EUR 25 million

Amsterdam, The Netherlands, May 30, 2019 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announces the launch of a private placement of new shares to raise approximately EUR 25 million from institutional investors (the "Placing"). Existing shareholders of the Company will not have pre-emptive rights in relation to the new shares to be issued. The new shares will rank pari passu in all respects with the currently issued and outstanding shares of the Company.

Following the Company's announcement on 17 April 2019 of its intention to acquire US-based CytoSen Therapeutics, Inc. ("CytoSen") in an all share deal, Kiadis Pharma intends to use the net proceeds of the Placing to:

Progress Kiadis' ATIR101 development, including the furtherance of Phase III trials, preparing for potential commercialization in Europe, and expanding ATIR manufacturing capacity
Progress CytoSen's pipeline products as well as general corporate purposes and other working capital needs
The new shares will be placed with institutional investors through an accelerated bookbuilding process and the subscription price and the number of shares to be issued in the Placing will be determined through this process. The bookbuilding period for the Placing will commence today with immediate effect and will close at short notice.

In relation to the Placing, the Company has, subject to customary exceptions and to the issuance of shares and granting of options to CytoSen shareholders and options holders pursuant to the CytoSen acquisition agreement, agreed to a lock-up undertaking not to issue further new shares for a period of 90 calendar days after the settlement date. In addition, and also subject to customary exceptions, the largest shareholders of the Company (funds represented by and/or affiliated with Life Sciences Partners and Draper Esprit, together representing 31.5% of the share capital of the Company) as well as all members of the Company's Management Board and Supervisory Board have agreed to a lock-up undertaking for a period of 90 calendar days after the settlement date on future share disposals.

Separately, the majority of the Kiadis Pharma shares issued to the CytoSen shareholders pursuant to the CytoSen acquisition agreement - i.e. the shares issued to CytoSen's Executive Chairman, CEO and founders - will be subject to a lock-up by the Company for a period of two years from closing, with the remainder of the shares subject to a lock-up for 180 days.

The Company will announce the final number of new shares placed and the subscription price in the Placing in a subsequent press release expected to be published before the beginning of trading on Euronext Amsterdam and Brussels on Friday, May 31, 2019.

The new shares will be admitted to trading on Euronext Amsterdam and Euronext Brussels on the basis of a listing prospectus, consisting of a registration document and a securities note, which will submitted to the Netherlands Authority for the Financial Markets (AFM) with a view to receiving its approval on or about Friday May 31, 2019, following which it will be made available free of charge on the Company's website (www.kiadis.com). In view of the bookbuild offering, the Company has posted an unapproved draft version of the registration document on its website.

Jefferies International Limited is acting as Sole Global Coordinator and Joint Bookrunner together with Piper Jaffray & Co, Inc.

For more information, please contact:

Kiadis Pharma:
Amy Sullivan, SVP, Corporate Affairs
Tel. +1-508-479-3480
a.sullivan@kiadis.com Optimum Strategic Communications:
Mary Clark, Supriya Mathur, Hollie Vile
Tel: +44 203 714 1787
David Brilleslijper (Amsterdam)
Tel: +31 610 942 514
kiadis@optimumcomms.com


About Kiadis Pharma
Founded in 1997, Kiadis Pharma, is a fully integrated biopharmaceutical company committed to developing innovative therapies for patients with late-stage blood cancers. With headquarters in Amsterdam, the Netherlands, Kiadis Pharma is reimagining medicine by leveraging the natural strengths of humanity and our collective immune system to source the best cells for life.

Kiadis Pharma is listed on the regulated market of Euronext Amsterdam and Euronext Brussels since July 2, 2015, under the symbol KDS. Learn more at kiadis.com.

About ATIR101
ATIR101TM is an investigational allodepleted T-cell immunotherapy product candidate, which is designed to be given after a haploidentical (genetically half-matched) hematopoietic stem cell transplantation (HSCT).

Administered as an adjunctive immunotherapeutic on top of HSCT, ATIR101 provides a single dose donor lymphocyte infusion (DLI) with functional, mature immune cells from a haploidentical family member. The T-cells in ATIR101 will help fight infections and remaining tumor cells, until the immune system has fully re-grown from stem cells in the transplanted graft.

In ATIR101, T-cells that would cause GVHD are depleted from the donor lymphocytes, using our photodepletion technology. At the same time, ATIR101 contains potential cancer-killing T-cells from the donor that could eliminate residual cancer cells and help prevent relapse of the disease.
Bio-belegger
0

Kiadis Pharma launches a private placement of new shares to raise
approximately EUR 25 million

Amsterdam, The Netherlands, May 30, 2019 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announces the launch of a private placement of new shares to raise approximately EUR 25 million from institutional investors (the "Placing"). Existing shareholders of the Company will not have pre-emptive rights in relation to the new shares to be issued. The new shares will rank pari passu in all respects with the currently issued and outstanding shares of the Company.

Following the Company's announcement on 17 April 2019 of its intention to acquire US-based CytoSen Therapeutics, Inc. ("CytoSen") in an all share deal, Kiadis Pharma intends to use the net proceeds of the Placing to:

Progress Kiadis' ATIR101 development, including the furtherance of Phase III trials, preparing for potential commercialization in Europe, and expanding ATIR manufacturing capacity
Progress CytoSen's pipeline products as well as general corporate purposes and other working capital needs
The new shares will be placed with institutional investors through an accelerated bookbuilding process and the subscription price and the number of shares to be issued in the Placing will be determined through this process. The bookbuilding period for the Placing will commence today with immediate effect and will close at short notice.

In relation to the Placing, the Company has, subject to customary exceptions and to the issuance of shares and granting of options to CytoSen shareholders and options holders pursuant to the CytoSen acquisition agreement, agreed to a lock-up undertaking not to issue further new shares for a period of 90 calendar days after the settlement date. In addition, and also subject to customary exceptions, the largest shareholders of the Company (funds represented by and/or affiliated with Life Sciences Partners and Draper Esprit, together representing 31.5% of the share capital of the Company) as well as all members of the Company's Management Board and Supervisory Board have agreed to a lock-up undertaking for a period of 90 calendar days after the settlement date on future share disposals.

Separately, the majority of the Kiadis Pharma shares issued to the CytoSen shareholders pursuant to the CytoSen acquisition agreement - i.e. the shares issued to CytoSen's Executive Chairman, CEO and founders - will be subject to a lock-up by the Company for a period of two years from closing, with the remainder of the shares subject to a lock-up for 180 days.

The Company will announce the final number of new shares placed and the subscription price in the Placing in a subsequent press release expected to be published before the beginning of trading on Euronext Amsterdam and Brussels on Friday, May 31, 2019.

The new shares will be admitted to trading on Euronext Amsterdam and Euronext Brussels on the basis of a listing prospectus, consisting of a registration document and a securities note, which will submitted to the Netherlands Authority for the Financial Markets (AFM) with a view to receiving its approval on or about Friday May 31, 2019, following which it will be made available free of charge on the Company's website (www.kiadis.com). In view of the bookbuild offering, the Company has posted an unapproved draft version of the registration document on its website.

Jefferies International Limited is acting as Sole Global Coordinator and Joint Bookrunner together with Piper Jaffray & Co, Inc.

For more information, please contact:

Kiadis Pharma:
Amy Sullivan, SVP, Corporate Affairs
Tel. +1-508-479-3480
a.sullivan@kiadis.com Optimum Strategic Communications:
Mary Clark, Supriya Mathur, Hollie Vile
Tel: +44 203 714 1787
David Brilleslijper (Amsterdam)
Tel: +31 610 942 514
kiadis@optimumcomms.com


About Kiadis Pharma
Founded in 1997, Kiadis Pharma, is a fully integrated biopharmaceutical company committed to developing innovative therapies for patients with late-stage blood cancers. With headquarters in Amsterdam, the Netherlands, Kiadis Pharma is reimagining medicine by leveraging the natural strengths of humanity and our collective immune system to source the best cells for life.

Kiadis Pharma is listed on the regulated market of Euronext Amsterdam and Euronext Brussels since July 2, 2015, under the symbol KDS. Learn more at kiadis.com.

About ATIR101
ATIR101TM is an investigational allodepleted T-cell immunotherapy product candidate, which is designed to be given after a haploidentical (genetically half-matched) hematopoietic stem cell transplantation (HSCT).

Administered as an adjunctive immunotherapeutic on top of HSCT, ATIR101 provides a single dose donor lymphocyte infusion (DLI) with functional, mature immune cells from a haploidentical family member. The T-cells in ATIR101 will help fight infections and remaining tumor cells, until the immune system has fully re-grown from stem cells in the transplanted graft.

In ATIR101, T-cells that would cause GVHD are depleted from the donor lymphocytes, using our photodepletion technology. At the same time, ATIR101 contains potential cancer-killing T-cells from the donor that could eliminate residual cancer cells and help prevent relapse of the disease.
[/quote]
mr.Franz
0
Goed nieuws!! Eindelijk de onzekerheid over de emissie weg. Nu kunnen we snel omhoog!
1.360 Posts, Pagina: « 1 2 3 4 5 6 ... 45 46 47 48 49 50 51 52 53 54 55 ... 64 65 66 67 68 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Plaats een reactie

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord

Direct naar Forum

Kiadis Pharma Meer »

Koers 5,090   Verschil -0,03 (-0,59%)
Laag 5,020   Volume 39.269
Hoog 5,155   Gem. Volume 100.163
17-okt-19 14:27
label premium

Kiadis: Erop of eronder

Het laatste advies leest u als IEX Premium-lid

Inloggen Ontdek Premium